Vaso’s Radical Surgery: A Leaner MedTech Player Emerges from Divestiture

PLAINVIEW, NY – August 14, 2026 – In the often-turbulent world of publicly traded companies, clarity of purpose can be the most valuable asset. Vaso Corporation (OTCQX: VASO) delivered a masterclass in this principle today, announcing second-quarter financial results that showcased not just a return to profitability, but the powerful early returns of a deliberate, and at times painful, strategic transformation. The company’s successful pivot from a diversified holding with legacy IT assets to a pure-play MedTech entity offers a compelling case study in the value of corporate focus.

For the quarter ending June 30, 2026, Vaso reported a net income of $542 thousand on revenues of $20.9 million. This marks a sharp reversal from the same period last year, which saw a net loss of $197 thousand. The underlying engine of this turnaround is a significant boost in efficiency and margin, a direct consequence of shedding non-core businesses. “Gross profit for the quarter was $13.1 million, an increase of $1.3 million, or 11.3%, year over year, as a result of higher revenue – despite the exclusion of the healthcare IT business that was sold in the fourth quarter of 2025 – and higher gross margin,” said Dr. Jun Ma, President and CEO of Vaso Corporation, in the company’s official announcement.

This performance is the culmination of a multi-year effort to streamline the business, a process that reached its conclusion just weeks ago. The journey involved two key divestitures: the sale of its VasoHealthcare IT business to Nano-X Imaging in late 2025, and more significantly, the recent sale of its NetWolves network service business to COEO Solutions for $14.5 million in cash on July 31, 2026. As Dr. Ma concluded, this move completes the company's “exit from the network and IT services business,” allowing it to focus its resources on healthcare. The numbers validate this strategy, showing a leaner operation capable of generating significantly higher operating income—$974 thousand in Q2 2026 versus a mere $93 thousand a year prior.

A Two-Pronged Healthcare Strategy

With its IT segment now consigned to the history books, Vaso stands on two core pillars: VasoHealthcare, its professional sales services arm, and VasoMedical, its proprietary device and software division. Each represents a distinct but complementary approach to the healthcare market.

VasoHealthcare is the engine of the company’s current revenue strength. It operates as the exclusive sales representative for GE HealthCare’s diagnostic imaging and ultrasound products in specific U.S. market segments. This long-standing partnership, recently extended through the end of 2030, is a cornerstone of Vaso’s stability. It provides a consistent, high-quality revenue stream tied to one of the world's premier medical technology brands. The success of this model was evident in the second quarter, where the professional sales services segment saw its revenue jump by a robust 20.0% year-over-year, driven by strong deliveries of GE HealthCare products. While this symbiotic relationship carries the inherent risk of dependence, it also provides Vaso with a front-row seat to cutting-edge innovation, allowing it to grow alongside a market leader.

If VasoHealthcare is the stable foundation, VasoMedical represents the company’s bet on its own innovation and future growth. This division designs and manufactures proprietary products, including the Biox series of non-invasive Holter monitors and ambulatory blood pressure recorders. More critically for its future, it also develops and operates the ARCS cloud-based SaaS platform for cardiac telemetry. This positions Vaso in the rapidly expanding markets for non-invasive diagnostics and remote patient monitoring. While a smaller contributor to revenue currently, the equipment segment saw a 31% revenue increase in the quarter, driven by strong performance in its China operations. The continued development and adoption of the ARCS platform, in particular, will be a key indicator of Vaso’s ability to transition from a service provider to a technology leader in its own right, competing with established players and agile startups in the digital health space.

A Case Study in Corporate Discipline

The story of Vaso’s transformation transcends a single earnings report. It reflects a broader industry trend where investors are rewarding focused execution over sprawling, often inefficient, diversification. By exiting the IT services business—a segment that, while generating revenue, had previously been a drag on operating income—Vaso has not only improved its margin profile but also clarified its narrative for the market.

The financial benefits of this discipline are clear. The $14.5 million cash infusion from the NetWolves sale bolsters an already healthy balance sheet, with cash and equivalents now standing at approximately $52.3 million. This war chest provides significant strategic flexibility, enabling potential investment in VasoMedical’s R&D, strategic acquisitions to complement its healthcare portfolio, or returns to shareholders. Furthermore, the company’s deferred revenue—a key indicator of future business—has grown to $41.5 million, up 8.9% from the prior year. This signals a strong order book and provides a degree of visibility that is highly prized by investors.

After a period that included a terminated merger agreement in 2024 and a complex unwinding of its diversified assets, Vaso Corporation now appears to be on a much clearer and more direct path. The company has effectively performed surgery on itself, excising non-core parts to improve the health of the whole. The immediate results are positive, and the stage is now set for a focused MedTech company to prove it can thrive in a competitive but opportunity-rich healthcare landscape.